What is Wedbush’s Forecast for Ardelyx FY2026 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX) – Equities research analysts at Wedbush reduced their FY2026 earnings per share estimates for shares of Ardelyx in a report issued on Friday, November 1st. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn $0.06 per share for the year, down from their previous estimate of $0.08. Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Ardelyx’s FY2027 earnings at $0.38 EPS and FY2028 earnings at $0.66 EPS.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Ardelyx in a report on Friday. StockNews.com raised Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Citigroup lowered their price target on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Ardelyx has an average rating of “Moderate Buy” and an average price target of $11.33.

Ardelyx Stock Performance

NASDAQ ARDX opened at $5.89 on Monday. The company’s 50 day moving average is $6.06 and its 200-day moving average is $6.32. The firm has a market cap of $1.39 billion, a P/E ratio of -19.63 and a beta of 0.92. Ardelyx has a 12-month low of $3.43 and a 12-month high of $10.13. The company has a quick ratio of 3.99, a current ratio of 4.21 and a debt-to-equity ratio of 0.68.

Institutional Investors Weigh In On Ardelyx

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its holdings in Ardelyx by 1,026.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,233 shares in the last quarter. Redwood Wealth Management Group LLC purchased a new position in shares of Ardelyx in the 2nd quarter valued at approximately $62,000. Coastal Bridge Advisors LLC bought a new stake in shares of Ardelyx during the second quarter valued at approximately $74,000. Helen Stephens Group LLC purchased a new stake in Ardelyx in the third quarter worth $76,000. Finally, Paloma Partners Management Co purchased a new position in Ardelyx during the first quarter valued at $86,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insider Buying and Selling at Ardelyx

In other news, insider David P. Rosenbaum sold 20,000 shares of Ardelyx stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $5.94, for a total value of $118,800.00. Following the transaction, the insider now owns 356,479 shares in the company, valued at approximately $2,117,485.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider David P. Rosenbaum sold 49,564 shares of the company’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $6.92, for a total transaction of $342,982.88. Following the completion of the sale, the insider now directly owns 301,946 shares in the company, valued at $2,089,466.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider David P. Rosenbaum sold 20,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the sale, the insider now directly owns 356,479 shares in the company, valued at approximately $2,117,485.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 212,126 shares of company stock worth $1,298,963 over the last ninety days. Insiders own 5.90% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.